Short-term efficacy of calcium fructoborate on subjects with knee discomfort: a comparative, double-blind, placebo-controlled clinical study

Zbigniew Pietrzkowski, Michael J Phelan, Robert Keller, Cynthia Shu, Ruby Argumedo, Tania Reyes-Izquierdo, Zbigniew Pietrzkowski, Michael J Phelan, Robert Keller, Cynthia Shu, Ruby Argumedo, Tania Reyes-Izquierdo

Abstract

Calcium fructoborate (CFB) at a dose of 110 mg twice per day was previously reported to improve knee discomfort during the first 14 days of treatment. In this study, 60 participants with self-reported knee discomfort were randomized into two groups receiving CFB or placebo. Initial levels of knee discomfort were evaluated by Western Ontario and McMaster Universities Arthritis Index (WOMAC) and McGill Pain Questionnaire (MPQ) scores at the beginning of the study and also at 7 and 14 days after treatment. Results showed that supplementation with CFB significantly improved knee discomfort in the study subjects; significant reductions of mean within-subject change in WOMAC and MPQ scores were observed for the CFB group compared to the placebo group at both 7 and 14 days after treatment. Estimated treatment differences for the MPQ score were -5.8 (P=0.0009) and -8.9 (P<0.0001) at Day 7 and 14, respectively. Estimated differences for the WOMAC score were -5.3 (P=0.06) and -13.73 (P<0.0001) at Day 7 and 14, respectively. Negative values indicate greater reductions in reported discomfort. On both Day 7 and Day 14, the trend was toward greater improvement in the CFB group. The placebo group did not exhibit any change in the WOMAC and MPQ scores. In conclusion, supplementation with 110 mg CFB twice per day was associated with improving knee discomfort during the 2 weeks of intake.

Keywords: CFB; McGill pain score; WOMAC score; joint discomfort.

References

    1. Miljkovic D, Scorei RI, Cimpoiaşu VM, Scorei ID. Calcium fructoborate: plant-based dietary boron for human nutrition. J Diet Suppl. 2009;6(3):211–226.
    1. Reyes-Izquierdo T, Nemzer B, Gonzalez AE, et al. Short-term intake of calcium fructoborate improves WOMAC and McGill scores and beneficially modulates biomarkers associated with knee osteoarthritis: a pilot clinical double-blinded placebo-controlled study. Am J Biomed Sci. 2012;4(2):111–122.
    1. Wagner CC, Ferraresi Curotto V, Pis Diez R, Baran EJ. Experimental and theoretical studies of calcium fructoborate. Biol Trace Elem Res. 2008;122(1):64–72.
    1. Scorei RI, Ciofrangeanu C, Ion R, et al. In vitro effects of calcium fructoborate upon production of inflammatory mediators by LPS-stimulated RAW 264.7 macrophages. Biol Trace Elem Res. 2010;135(1–3):334–344.
    1. Scorei ID, Scorei RI. Calcium fructoborate helps control inflammation associated with diminished bone health. Biol Trace Elem Res. 2013;155(3):315–321.
    1. Scorei R, Mitrut P, Petrisor I, Scorei I. A double-blind, placebo-controlled pilot study to evaluate the effect of calcium fructoborate on systemic inflammation and dyslipidemia markers for middle-aged people with primary osteoarthritis. Biol Trace Elem Res. 2011;144(1–3):253–263.
    1. Sharif M, Shepstone L, Elson CJ, Dieppe PA, Kirwan JR. Increased serum C reactive protein may reflect events that precede radiographic progression in osteoarthritis of the knee. Ann Rheum Dis. 2000;59(1):71–74.
    1. Scorei RI, Rotaru P. Calcium fructoborate – potential anti-inflammatory agent. Biol Trace Elem Res. 2011;143(3):1223–1238.
    1. Scorei R. Is boron a prebiotic element? A mini-review of the essentiality of boron for the appearance of life on earth. Orig Life Evol Biosph. 2012;42(1):3–17.
    1. Militaru C, Donoiu I, Craciun A, Scorei ID, Bulearca AM, Scorei RI. Oral resveratrol and calcium fructoborate supplementation in subjects with stable angina pectoris: effects on lipid profiles, inflammation markers, and quality of life. Nutrition. 2013;29(1):178–183.
    1. Neugebauer V, Han J, Adwanikar H, Fu Y, Ji G. Techniques for assessing knee joint pain in arthritis. Mol Pain. 2007;3:8.
    1. Calmbach WL, Hutchens M. Evaluation of patients presenting with knee pain: Part II. Differential diagnosis. Am Fam Physician. 2003;68(5):917–922.
    1. Bush TM, Shlotzhauer TL, Imai K. Nonsteroidal anti-inflammatory drugs. Proposed guidelines for monitoring toxicity. West J Med. 1991;155(1):39–42.
    1. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15(12):1833–1840.
    1. Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain. 1975;1(3):277–299.
    1. Melzack R. The McGill pain questionnaire: from description to measurement. Anesthesiology. 2005;103(1):199–202.
    1. Gandhi R, Tsvetkov D, Dhottar H, Davey JR, Mahomed NN. Quantifying the pain experience in hip and knee osteoarthritis. Pain Res Manag. 2010;15(4):224–228.
    1. Diggle P, Heagerty P, Liang KY, Zeger SL. Analysis of Longitudinal Data. 2nd ed. New York: Oxford University Press; 2009.
    1. Rotaru P, Scorei R, Harabor A, Dumitru MD. Thermal analysis of a calcium fructoborate sample. Thermochim Acta. 2010;506:8–13.
    1. Scorei IR. Calcium fructoborate: plant-based dietary boron as potential medicine for cancer therapy. Front Biosci (Schol Ed) 2011;3:205–215.
    1. Scorei R, Ciubar R, Ciofrangeanu CM, Mitran V, Cimpean A, Iordachescu D. Comparative effects of boric acid and calcium fructoborate on breast cancer cells. Biol Trace Elem Res. 2008;122(3):197–205.
    1. Scorei R, Ciubar R, Iancu C, Mitran V, Cimpean A, Iordachescu D. In vitro effects of calcium fructoborate on fMLP-stimulated human neutrophil granulocytes. Biol Trace Elem Res. 2007;118(1):27–37.
    1. Scorei RI, Popa R. Sugar-borate esters – potential chemical agents in prostate cancer chemoprevention. Anticancer Agents Med Chem. 2013;13(6):901–909.
    1. Scorei RI, Popa R. Boron-containing compounds as preventive and chemotherapeutic agents for cancer. Anticancer Agents Med Chem. 2010;10(4):346–351.
    1. Dinca L, Scorei R. Boron in human nutrition and its regulations use. J Nutr Ther. 2013;2(1):22–29.
    1. Hunt CD. Boron. In: Coates PM, Betz JM, Blackman MR, editors. Encyclopedia of dietary supplements. 2nd ed. New York: Informa Healthcare; 2010. pp. 82–90.
    1. Meacham S, Karakas S, Wallace A, Altun F. Boron in human health: evidence for dietary recommendations and public policies. Open Miner Process J. 2010;3:36–53.
    1. Devirian TA, Volpe SL. The physiological effects of dietary boron. Crit Rev Food Sci Nutr. 2003;43(2):219–231.
    1. Rainey CJ, Nyquist LA, Coughlin JR, Downing RG. Dietary Boron Intake in the United States: CSFII 1994–1996. J Food Compos Anal. 2002;15(3):237–250.
    1. Pearle AD, Scanzello CR, George S, et al. Elevated high-sensitivity C-reactive protein levels are associated with local inflammatory findings in patients with osteoarthritis. Osteoarthritis Cartilage. 2007;15(5):516–523.
    1. Sarzi-Puttini P, Cimmino MA, Scarpa R, et al. Osteoarthritis: an overview of the disease and its treatment strategies. Semin Arthritis Rheum. 2005;35(1 Suppl 1):1–10.
    1. Creamer P, Lethbridge-Cejku M, Hochberg MC. Determinants of pain severity in knee osteoarthritis: effect of demographic and psychosocial variables using 3 pain measures. J Rheumatol. 1999;26(8):1785–1792.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj